These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 36642233)
1. Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: a real-life, single-centre experience. Karruli A; Massa A; Andini R; Marrazzo T; Ruocco G; Zampino R; Durante-Mangoni E Int J Antimicrob Agents; 2023 Feb; 61(2):106723. PubMed ID: 36642233 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795 [TBL] [Abstract][Full Text] [Related]
3. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
4. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675 [TBL] [Abstract][Full Text] [Related]
5. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection. Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176 [TBL] [Abstract][Full Text] [Related]
6. Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections. Gavaghan V; Miller JL; Dela-Pena J Infection; 2023 Apr; 51(2):475-482. PubMed ID: 36201152 [TBL] [Abstract][Full Text] [Related]
7. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety. Lee YR; Yeo S Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of cefiderocol for off-label treatment indications: A systematic review. Babidhan R; Lewis A; Atkins C; Jozefczyk NJ; Nemecek BD; Montepara CA; Gionfriddo MR; Zimmerman DE; Covvey JR; Guarascio AJ Pharmacotherapy; 2022 Jul; 42(7):549-566. PubMed ID: 35611627 [TBL] [Abstract][Full Text] [Related]
14. Real-life Data on Cefiderocol Efficacy and Safety to Treat Multidrug-Resistant Campogiani L; Crea AMA; Minardi ML; Ansaldo L; Coppola L; Compagno M; Vitale P; Spalliera I; Malagnino V; Teti E; D'agostini C; Pennacchiotti C; Abate DN; Celeste MG; Andreoni M; Iannetta M; Sarmati L Open Forum Infect Dis; 2023 Dec; 10(12):ofad627. PubMed ID: 38156051 [TBL] [Abstract][Full Text] [Related]
15. In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria. Yamano Y Clin Infect Dis; 2019 Nov; 69(Suppl 7):S544-S551. PubMed ID: 31724049 [TBL] [Abstract][Full Text] [Related]
16. Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii. Falcone M; Tiseo G; Leonildi A; Della Sala L; Vecchione A; Barnini S; Farcomeni A; Menichetti F Antimicrob Agents Chemother; 2022 May; 66(5):e0214221. PubMed ID: 35311522 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model. Monogue ML; Tsuji M; Yamano Y; Echols R; Nicolau DP Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848004 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections. Drwiega EN; Griffith NC; Danziger LH Expert Opin Drug Metab Toxicol; 2022 Apr; 18(4):245-259. PubMed ID: 35594628 [TBL] [Abstract][Full Text] [Related]
20. Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Mazzitelli M; Gregori D; Sasset L; Trevenzoli M; Scaglione V; Lo Menzo S; Marinello S; Mengato D; Venturini F; Tiberio I; Navalesi P; Cattelan A Microorganisms; 2023 Apr; 11(4):. PubMed ID: 37110408 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]